Peroxisome proliferator-activated aeceptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells

Jeffrey M. Gimble, Claudius E. Robinson, Xiying Wu, Katherine A. Kelly, Brenda R. Rodriguez, Steven A. Kliewer, Jurgen M. Lehmann, David C. Morris

Research output: Contribution to journalArticle

267 Citations (Scopus)

Abstract

The thiazolidinediones improve insulin sensitivity in animal models and have promise as potent oral antidiabetic agents. Their clinical use has been limited because of the resulting anemia and cardiac hypertrophy. Some compounds of this class have been reported to induce bone marrow fat accumulation in animals, and this effect could account for the observed anemia. We examined the biological mechanism contributing to this phenomenon. The thiazolidinediones BRL49653 and pioglitazone induced adipocyte differentiation in the BMS2 bone marrow stromal cell line in a dose- and time-dependent manner. These actions were further enhanced by the presence of glucocorticoids and other adipogenic agonists. The thiazolidinediones increased the mRNA levels of adipocyte-specific genes, including that of their receptor, the peroxisome proliferator-activated receptor-γ (PPARγ). In contrast, mRNA levels of genes encoding other PPAR family members (PPARα, PPARδ, or NUC-1) were unchanged or decreased. Thiazolidinedione treatment of primary bone marrow stromal cells elicited a comparable dose-dependent response. Using a polyclonal antibody, PPARγ was detected in protein lysates from adipose-rich bone marrow. Thus, thiazolidinedione directly regulates bone marrow stromal cell differentiation; induced PPARγ expression may play a key regulatory role in this process.

Original languageEnglish (US)
Pages (from-to)1087-1094
Number of pages8
JournalMolecular Pharmacology
Volume50
Issue number5
StatePublished - Nov 1996

Fingerprint

Peroxisome Proliferators
Thiazolidinediones
Adipogenesis
Peroxisome Proliferator-Activated Receptors
Mesenchymal Stromal Cells
rosiglitazone
pioglitazone
Adipocytes
Anemia
Bone Marrow
Messenger RNA
Cardiomegaly
Hypoglycemic Agents
Glucocorticoids
Genes
Insulin Resistance
Cell Differentiation
Animal Models
Fats
Cell Line

ASJC Scopus subject areas

  • Pharmacology

Cite this

Gimble, J. M., Robinson, C. E., Wu, X., Kelly, K. A., Rodriguez, B. R., Kliewer, S. A., ... Morris, D. C. (1996). Peroxisome proliferator-activated aeceptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Molecular Pharmacology, 50(5), 1087-1094.

Peroxisome proliferator-activated aeceptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. / Gimble, Jeffrey M.; Robinson, Claudius E.; Wu, Xiying; Kelly, Katherine A.; Rodriguez, Brenda R.; Kliewer, Steven A.; Lehmann, Jurgen M.; Morris, David C.

In: Molecular Pharmacology, Vol. 50, No. 5, 11.1996, p. 1087-1094.

Research output: Contribution to journalArticle

Gimble, JM, Robinson, CE, Wu, X, Kelly, KA, Rodriguez, BR, Kliewer, SA, Lehmann, JM & Morris, DC 1996, 'Peroxisome proliferator-activated aeceptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells', Molecular Pharmacology, vol. 50, no. 5, pp. 1087-1094.
Gimble, Jeffrey M. ; Robinson, Claudius E. ; Wu, Xiying ; Kelly, Katherine A. ; Rodriguez, Brenda R. ; Kliewer, Steven A. ; Lehmann, Jurgen M. ; Morris, David C. / Peroxisome proliferator-activated aeceptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. In: Molecular Pharmacology. 1996 ; Vol. 50, No. 5. pp. 1087-1094.
@article{160461a975b2470989b7cfc84fa5be91,
title = "Peroxisome proliferator-activated aeceptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells",
abstract = "The thiazolidinediones improve insulin sensitivity in animal models and have promise as potent oral antidiabetic agents. Their clinical use has been limited because of the resulting anemia and cardiac hypertrophy. Some compounds of this class have been reported to induce bone marrow fat accumulation in animals, and this effect could account for the observed anemia. We examined the biological mechanism contributing to this phenomenon. The thiazolidinediones BRL49653 and pioglitazone induced adipocyte differentiation in the BMS2 bone marrow stromal cell line in a dose- and time-dependent manner. These actions were further enhanced by the presence of glucocorticoids and other adipogenic agonists. The thiazolidinediones increased the mRNA levels of adipocyte-specific genes, including that of their receptor, the peroxisome proliferator-activated receptor-γ (PPARγ). In contrast, mRNA levels of genes encoding other PPAR family members (PPARα, PPARδ, or NUC-1) were unchanged or decreased. Thiazolidinedione treatment of primary bone marrow stromal cells elicited a comparable dose-dependent response. Using a polyclonal antibody, PPARγ was detected in protein lysates from adipose-rich bone marrow. Thus, thiazolidinedione directly regulates bone marrow stromal cell differentiation; induced PPARγ expression may play a key regulatory role in this process.",
author = "Gimble, {Jeffrey M.} and Robinson, {Claudius E.} and Xiying Wu and Kelly, {Katherine A.} and Rodriguez, {Brenda R.} and Kliewer, {Steven A.} and Lehmann, {Jurgen M.} and Morris, {David C.}",
year = "1996",
month = "11",
language = "English (US)",
volume = "50",
pages = "1087--1094",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

TY - JOUR

T1 - Peroxisome proliferator-activated aeceptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells

AU - Gimble, Jeffrey M.

AU - Robinson, Claudius E.

AU - Wu, Xiying

AU - Kelly, Katherine A.

AU - Rodriguez, Brenda R.

AU - Kliewer, Steven A.

AU - Lehmann, Jurgen M.

AU - Morris, David C.

PY - 1996/11

Y1 - 1996/11

N2 - The thiazolidinediones improve insulin sensitivity in animal models and have promise as potent oral antidiabetic agents. Their clinical use has been limited because of the resulting anemia and cardiac hypertrophy. Some compounds of this class have been reported to induce bone marrow fat accumulation in animals, and this effect could account for the observed anemia. We examined the biological mechanism contributing to this phenomenon. The thiazolidinediones BRL49653 and pioglitazone induced adipocyte differentiation in the BMS2 bone marrow stromal cell line in a dose- and time-dependent manner. These actions were further enhanced by the presence of glucocorticoids and other adipogenic agonists. The thiazolidinediones increased the mRNA levels of adipocyte-specific genes, including that of their receptor, the peroxisome proliferator-activated receptor-γ (PPARγ). In contrast, mRNA levels of genes encoding other PPAR family members (PPARα, PPARδ, or NUC-1) were unchanged or decreased. Thiazolidinedione treatment of primary bone marrow stromal cells elicited a comparable dose-dependent response. Using a polyclonal antibody, PPARγ was detected in protein lysates from adipose-rich bone marrow. Thus, thiazolidinedione directly regulates bone marrow stromal cell differentiation; induced PPARγ expression may play a key regulatory role in this process.

AB - The thiazolidinediones improve insulin sensitivity in animal models and have promise as potent oral antidiabetic agents. Their clinical use has been limited because of the resulting anemia and cardiac hypertrophy. Some compounds of this class have been reported to induce bone marrow fat accumulation in animals, and this effect could account for the observed anemia. We examined the biological mechanism contributing to this phenomenon. The thiazolidinediones BRL49653 and pioglitazone induced adipocyte differentiation in the BMS2 bone marrow stromal cell line in a dose- and time-dependent manner. These actions were further enhanced by the presence of glucocorticoids and other adipogenic agonists. The thiazolidinediones increased the mRNA levels of adipocyte-specific genes, including that of their receptor, the peroxisome proliferator-activated receptor-γ (PPARγ). In contrast, mRNA levels of genes encoding other PPAR family members (PPARα, PPARδ, or NUC-1) were unchanged or decreased. Thiazolidinedione treatment of primary bone marrow stromal cells elicited a comparable dose-dependent response. Using a polyclonal antibody, PPARγ was detected in protein lysates from adipose-rich bone marrow. Thus, thiazolidinedione directly regulates bone marrow stromal cell differentiation; induced PPARγ expression may play a key regulatory role in this process.

UR - http://www.scopus.com/inward/record.url?scp=0029847076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029847076&partnerID=8YFLogxK

M3 - Article

C2 - 8913339

AN - SCOPUS:0029847076

VL - 50

SP - 1087

EP - 1094

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 5

ER -